The system provides more than 27,000 genotypes a day. Users can add IFC controllers and thermal cyclers to a single EP1 Reader in order to generate more than 200,000 genotypes per day, the company said.
Osmetech’s CYP450 2C9 Test, Fluidigm EP1 Genotyping System
Osmetech has launched a genetic test for CYP450 2C9 drug metabolism. The test identifies polymorphisms in the CYP2C9 gene, which the company said is associated with the metabolism of 10 percent of all drugs, including non-steroidal anti-inflammatory drugs, anticoagulants, anti-epileptic agents, cholesterol-lowering drugs, and anti-diabetic agents.
The CYP2C9 test is available for research use only on the company’s eSensor XT-8 System. The company said it “may also seek FDA approval” for the test.
Fluidigm this week launched its EP1 system for high-throughput SNP genotyping and digital PCR. The EP1 system offers integrated fluidic circuit-based genotyping in a desktop-sized configuration, the company said.
Fluidigm said that the EP1 system delivers “the highest quality SNP genotyping results on the market,” with call rates of 99 percent or more and 99.75 percent or greater accuracy.